MANHARD KIMBERLY
SEC Form 4 insider trading activity
MANHARD KIMBERLY has filed 2 SEC Form 4 filings (5 transaction rows) across 1 company, with disclosures dating back to 2026. 2 of those filings fall inside the rolling window. Most recent filing: Sep 15, 2026.
On the most recent filing, MANHARD KIMBERLY is listed as Director at Inhibrx Biosciences, Inc. Inside the rolling window, MANHARD KIMBERLY reported no open-market purchases and 5 open-market sales totaling $279K in INBX. The largest disclosed transaction in the window is a sale of 500 INBX shares on Sep 9, 2026, worth $58K.
Companies traded
Other insiders at INBX
Insider Buying
$0
reported purchases (SEC code P)
Insider Selling
$279K
reported sales (SEC code S)
Companies
1
in the rolling window
Frequently asked questions
How many SEC Form 4 filings has MANHARD KIMBERLY made?
MANHARD KIMBERLY has filed 2 SEC Form 4 filings (5 transaction rows) across 1 company since 2026.
Which companies does MANHARD KIMBERLY trade?
MANHARD KIMBERLY has filed SEC Form 4 disclosures for 1 company, including INBX.
When was MANHARD KIMBERLY's most recent SEC Form 4 filing?
MANHARD KIMBERLY's most recent SEC Form 4 filing on Tracefour is dated Sep 15, 2026.
What is MANHARD KIMBERLY's total buy and sell value in the current window?
Inside the rolling retention window, MANHARD KIMBERLY bought $0 and sold $279K based on SEC Form 4 filings.
What was MANHARD KIMBERLY's largest disclosed transaction?
The largest disclosed transaction in the current window is a sale of 500 INBX shares on 2026-09-09, worth $58K, per SEC Form 4 filings.